All > Hodgkins Lymphoma

XL114 for Non-Hodgkin's Lymphoma

Exelixis Clinical Site #3, Tucson, AZ
Non-Hodgkin's Lymphoma+4 More ConditionsXL114 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new cancer drug, XL114, to see if it is safe and effective. The study will also help determine the best dose of the drug.

Eligible Conditions
  • Non-Hodgkin's Lymphoma
  • Mantle Cell Lymphoma
  • Small Lymphocytic Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Chronic Lymphocytic Leukemia

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1

Similar Trials

1
SQ3370
1
XB002
1
IGM-8444

Study Objectives

4 Primary · 17 Secondary · Reporting Duration: 4-6 months

4-6 months
Cohort-Expansion Stage: Antitumor Activity of XL114 (Duration of Response [DOR])
Cohort-Expansion Stage: Antitumor Activity of XL114 (Duration of Response)
Cohort-Expansion Stage: Antitumor Activity of XL114 (Objective Response Rate [ORR])
Cohort-Expansion Stage: Antitumor Activity of XL114 (Objective Response Rate)
Cohort-Expansion Stage: Antitumor Activity of XL114 (Progression Free Survival [PFS])
Cohort-Expansion Stage: Antitumor Activity of XL114 (Progression Free Survival)
Cohort-Expansion Stage: Objective Rate Response (ORR)
Cohort-Expansion Stage: Objective Response Rate (ORR)
Cohort-Expansion Stage: Overall Survival (OS) of XL114
Cohort-Expansion Stage: Overall Survival of XL114
Dose-Escalation Stage: Apparent Clearance (CL/F)
Dose-Escalation Stage: Area Under the Plasma Concentration-Time Curve Over the Last 24-hour Dosing Interval (AUC 0-24)
Dose-Escalation Stage: Maximum Plasma Concentration (Cmax)
Dose-Escalation Stage: RD and/or MTD for XL114
Dose-Escalation Stage: Recommended Dose (RD) and/or Maximum Tolerated Dose (MTD) for XL114
Dose-Escalation Stage: Terminal Half-Life
Dose-Escalation Stage: Time to Maximum Plasma Concentration (Tmax)
Safety of XL114, as evaluated by Adverse Events
Safety of XL114, as evaluated by Adverse Events (AEs)
Tolerability of XL114, as evaluated by Dose Intensity, Dose Modifications, and Study Discontinuation due to AE
Tolerability of XL114, as evaluated by Dose Intensity, Dose Modifications, and Study Discontinuation due to AEs

Trial Safety

Phase-Based Safety

1 of 3

Similar Trials

1
SQ3370
1
XB002
1
IGM-8444

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

2 Treatment Groups

XL114 Dose-Escalation Cohorts
1 of 2
XL114 Expansion Cohorts
1 of 2

Experimental Treatment

144 Total Participants · 2 Treatment Groups

Primary Treatment: XL114 · No Placebo Group · Phase 1

XL114 Dose-Escalation Cohorts
Drug
Experimental Group · 1 Intervention: XL114 · Intervention Types: Drug
XL114 Expansion Cohorts
Drug
Experimental Group · 1 Intervention: XL114 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 4-6 months

Who is running the clinical trial?

ExelixisLead Sponsor
110 Previous Clinical Trials
17,804 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a type of lymphoma called ABC-DLBCL, MCL, or SLL that fits the specific criteria for this study.
References

Frequently Asked Questions

What are the desired end-results of this experiment?

"This clinical trial aims to assess the objective response rate (ORR) of XL114 over a four-to-six month period. Secondary objectives include evaluating antitumor activity through progression free survival, overall survival duration, and tolerability as measured by dose intensity, modifications, and study discontinuation due to adverse effects." - Anonymous Online Contributor

Unverified Answer

Has XL114 attained regulatory clearance from the FDA?

"Our experts at Power rate XL114's safety as a 1, due to the limited amount of evidence currently available from this Phase 1 trial." - Anonymous Online Contributor

Unverified Answer

Does this experiment have any open positions for those seeking to participate?

"Clinicaltrials.gov confirms that this clinical trial, initially posted on April 12th 2022, is currently accepting enrolment applications. The study was last edited on September 1st of the same year." - Anonymous Online Contributor

Unverified Answer

Can you provide an estimate of the aggregate amount of people participating in this clinical investigation?

"Exelixis, the trial's sponsor, must recruit 144 eligible participants located in multiple sites including Exelixis Clinical Site #2 in Spokane, Washington and Exelixis Clinical Site #1 in Indianapolis, Indiana." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top